You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 6,488,933

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,488,933

Title:	Preparations for the treatment of T cell mediated diseases
Abstract:	Metabolizable lipid emulsions, such as Intralipid and Lipofundin, are excellent vehicles for peptide therapy of autoimmune diseases and of other TH1 T cell mediated diseases or conditions, as it promotes a TH1 to TH2 cytokine shift. Such emulsions may be used in conjunction with an antigen recognized by inflammatory T cells associated with the pathogenesis of a T cell mediated disease or condition for the therapeutic treatment of such
Inventor(s):	Cohen; Irun R. (Rehovot, IL), Elias; Dana (Rehovot, IL), Shinitzky; Meir (Kfar Shmaryahu, IL)
Assignee:	Yeda Research and Development Co. Ltd. (Rehovot, IL)
Application Number:	08/981,861
Patent Claims:	1. A composition consisting essentially of an antigen and a carrier, wherein the antigen is recognized by inflammatory T cells associated with the pathogenesis if diabetes and is peptide p277 (residues 437-460 of SEQ ID NO:1) or peptide p277 (Val.sup.6 -Val.sup.11) (SEQ ID NO:4), and wherein the carrier induces a TH1.fwdarw.TH2 shift in the cytokines produced by said T cells and is a fat emulsion consisting essentially of 10-20 % triglycerides of plant and/or animal origin, 1.2-2.4% phospholipids of plant and/or animal origin, 2.25-4.5% osmoregulator, 0-0.05% antioxidant, and sterile water. 2. The composition according to claim 1, wherein the triglycerides are of plant origin. 3. The composition according to claim 2, wherein the triglyceride is derived from soybean, corronseed, coconut, or olive plants. 4. The composition according to claim 1, wherein the phospholipids are of animal origin. 5. The composition according to claim 4, wherein the phosolipids are derived from egg yolk or bovine serum. 6. The composition according to claim 1, wherein the osmo-regulator is glycerol, sorbitol or xylitol. 7. The composition according to claim 1, wherein the flat emulsion comprises 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol and sterile water.

Details for Patent 6,488,933

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2015-07-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.